LNPEP and early-onset autosomal dominant Alzheimer disease: Preclinical studies have demonstrated the potential of IRAP inhibitors as cognitive enhancers and for treating neurodegenerative conditions such as Alzheimer's disease, which are characterized by progressive cognitive and memory decline.